Immune checkpoint biology in health & disease: Immune checkpoint biology and autoimmunity in cancer patients.

Van Mol, Pierre; Donders, Elena; Lambrechts, Diether; Wauters, Els

Van Mol, Pierre; Donders, Elena; Lambrechts, Diether; Wauters, Els.

Afiliación

Van Mol P; VIB - CCB Laboratory of Translational Genetics, KU Leuven, Leuven, Belgium; Pneumology - Respiratory Oncology, University Hospitals Leuven, Leuven, Belgium.
Donders E; VIB - CCB Laboratory of Translational Genetics, KU Leuven, Leuven, Belgium; Pneumology - Respiratory Oncology, University Hospitals Leuven, Leuven, Belgium.
Lambrechts D; VIB - CCB Laboratory of Translational Genetics, KU Leuven, Leuven, Belgium.
Wauters E; Pneumology - Respiratory Oncology, University Hospitals Leuven, Leuven, Belgium. Electronic address: els.wauters@uzleuven.be.

Int Rev Cell Mol Biol ; 382: 181-206, 2024.

Article en En | MEDLINE | ID: mdl-38225103

ABSTRACT

ABSTRACT

Immune checkpoints (ICs) play a central role in maintaining immune homoeostasis. The discovery that tumours use this physiological mechanism to avoid elimination by the immune system, opened up avenues for therapeutic targeting of ICs as a novel way of treating cancer. However, this therapy a new array of autoimmune side effects, termed immune-related adverse events (irAEs). In this narrative review, we first recapitulate the physiological function of ICs that are approved targets for cancer immunotherapy (CTLA-4, PD-(L)1 and LAG-3), as the groundwork to critically discuss current knowledge on irAEs. Specifically, we summarize clinical aspects and examine a molecular classification and predisposing factors of irAEs. Finally, we discuss irAE treatment, particularly emphasizing how molecular knowledge is changing the current treatment paradigm.

Asunto(s)

Antineoplásicos Inmunológicos; Neoplasias; Humanos; Antineoplásicos Inmunológicos/uso terapéutico; Autoinmunidad; Neoplasias/patología; Inmunoterapia; Biología

Palabras clave

B-cell; CTLA-4; Complement; Cytokine; Cytokine therapy; Cytotoxic T-lymphocyte-associated protein 4; Immune-related adverse event; IrAE; LAG-3; Lymphocyte-activation gene 3; PD-1; PD-L1; Programmed cell death protein 1; Programmed death-ligand 1; T-cell

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antineoplásicos Inmunológicos / Neoplasias Límite: Humans Idioma: En Revista: Int Rev Cell Mol Biol Asunto de la revista: BIOLOGIA MOLECULAR Año: 2024 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Países Bajos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google